Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 103

    1.

    Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial.

    Munafò MR, Johnstone EC, Murphy MF, Aveyard P.

    Nicotine Tob Res. 2009 Apr;11(4):404-7. Epub 2009 Mar 8.PMID: 19273465 [PubMed - indexed for MEDLINE]Related articles

    2.

    Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.

    Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, Kaufmann V, Restine S, Hawk L, Niaura R, Berrettini W.

    Neuropsychopharmacology. 2006 Jan;31(1):231-42.PMID: 16123753 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood.

    Cinciripini P, Wetter D, Tomlinson G, Tsoh J, De Moor C, Cinciripini L, Minna J.

    Nicotine Tob Res. 2004 Apr;6(2):229-39.PMID: 15203796 [PubMed - indexed for MEDLINE]Related articles

    4.

    Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.

    David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafò MR, Shields PG, Lerman C, Strong D, McCaffery J, Niaura R.

    Nicotine Tob Res. 2007 Aug;9(8):821-33. Erratum in: Nicotine Tob Res. 2007 Nov;9(11):1243. PMID: 17654295 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence.

    Dahl JP, Jepson C, Levenson R, Wileyto EP, Patterson F, Berrettini WH, Lerman C.

    Pharmacogenomics J. 2006 May-Jun;6(3):194-9.PMID: 16402081 [PubMed - indexed for MEDLINE]Related articles

    6.

    Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.

    David SP, Strong DR, Munafò MR, Brown RA, Lloyd-Richardson EE, Wileyto PE, Evins EA, Shields PG, Lerman C, Niaura R.

    Nicotine Tob Res. 2007 Dec;9(12):1251-7.PMID: 18058343 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Neurotransmission-related genetic polymorphisms, negative affectivity traits, and gender predict tobacco abstinence symptoms across 44 days with and without nicotine patch.

    Gilbert DG, Zuo Y, Rabinovich NE, Riise H, Needham R, Huggenvik JI.

    J Abnorm Psychol. 2009 May;118(2):322-34.PMID: 19413407 [PubMed - indexed for MEDLINE]Related articles

    8.

    A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation.

    Welton NJ, Johnstone EC, David SP, Munafò MR.

    Nicotine Tob Res. 2008 Jan;10(1):231-40.PMID: 18188764 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data.

    Munafò MR, Timpson NJ, David SP, Ebrahim S, Lawlor DA.

    Nicotine Tob Res. 2009 Jan;11(1):64-76. Epub 2009 Jan 27. Review.PMID: 19246443 [PubMed - indexed for MEDLINE]Related articles

    10.

    Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial.

    Ray R, Jepson C, Wileyto EP, Dahl JP, Patterson F, Rukstalis M, Pinto A, Berrettini W, Lerman C.

    Nicotine Tob Res. 2007 Nov;9(11):1237-41.PMID: 17978999 [PubMed - indexed for MEDLINE]Related articles

    11.

    Nicotine replacement therapy for smoking cessation.

    Silagy C, Mant D, Fowler G, Lancaster T.

    Cochrane Database Syst Rev. 2000;(3):CD000146. Review. Update in: Cochrane Database Syst Rev. 2001;(3):CD000146. PMID: 10908462 [PubMed - indexed for MEDLINE]Related articles

    12.

    Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial.

    Johnstone EC, Elliot KM, David SP, Murphy MF, Walton RT, Munafò MR.

    Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1065-9.PMID: 17548664 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Lack of effect of D2 dopamine receptor TaqI A polymorphism on smoking cessation.

    Berlin I, Covey LS, Jiang H, Hamer D.

    Nicotine Tob Res. 2005 Oct;7(5):725-8.PMID: 16191743 [PubMed - indexed for MEDLINE]Related articles

    14.

    Association of the mu-opioid receptor gene with smoking cessation.

    Munafò MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC.

    Pharmacogenomics J. 2007 Oct;7(5):353-61. Epub 2007 Jan 16.PMID: 17224915 [PubMed - indexed for MEDLINE]Related articles

    15.

    Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch.

    Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, Griffiths SE, Walton RT.

    Pharmacogenetics. 2004 Feb;14(2):83-90.PMID: 15077009 [PubMed - indexed for MEDLINE]Related articles

    16.

    Nicotine replacement therapy for smoking cessation.

    Silagy C, Mant D, Fowler G, Lancaster T.

    Cochrane Database Syst Rev. 2000;(2):CD000146. Review. Update in: Cochrane Database Syst Rev. 2000;(3):CD000146. PMID: 10796494 [PubMed - indexed for MEDLINE]Related articles

    17.

    Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch.

    David SP, Munafò MR, Murphy MF, Proctor M, Walton RT, Johnstone EC.

    Pharmacogenomics J. 2008 Apr;8(2):122-8. Epub 2007 Mar 27.PMID: 17387332 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

    Morton LM, Wang SS, Bergen AW, Chatterjee N, Kvale P, Welch R, Yeager M, Hayes RB, Chanock SJ, Caporaso NE.

    Pharmacogenet Genomics. 2006 Dec;16(12):901-10.PMID: 17108814 [PubMed - indexed for MEDLINE]Related articles

    19.

    A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

    Robles GI, Singh-Franco D, Ghin HL.

    Clin Ther. 2008 May;30(5):800-12. Review.PMID: 18555928 [PubMed - indexed for MEDLINE]Related articles

    20.

    Nicotine replacement therapy for smoking cessation.

    Silagy C, Lancaster T, Stead L, Mant D, Fowler G.

    Cochrane Database Syst Rev. 2002;(4):CD000146. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD000146. PMID: 12519537 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data